At BaseLaunch, we incubate and accelerate therapeutic ventures. We have supported 18 ventures to date. Since supporting our first ventures in early 2018, nine of our portfolio companies have, in total, raised over $450 million in financing – with an average of $30M series A raise - from European and US Venture fund (among others Pureos Bioventures, NEA, Syncona, Sofinnova, Versant Ventures, the Novartis Venture Fund, Pfizer Ventures, Forbion, Boehringer Ingelheim Venture Fund, Sunstone Life Science Ventures, Morningside Venture Investments, Jeito Capital, Novo Holdings and more). Additional companies raised initial seed financings, several collaborations have been initiated and one company has been sold. BaseLaunch was initiated to help launch and grow the next generation of biotech companies by working in close collaboration with key players from the biotech sector, leading pharmaceutical companies, and venture funds. Our partners are Roche, Pureos Bioventures, Roivant Sciences, Bridge Biotherapeutics, CSL Behring, Johnson & Johnson, and China Medical System.BaseLaunch offers financing but also much more, including access to our partners, global biopharma and investors; assistance with the company and team build-out; access to labs & related infrastructure where needed. We ensure our ventures become deeply embedded in what is arguably Europe's strongest biotech ecosystem. The Basel Area touts academia and life science industry, a great network of talent and a hotbed for innovation.BaseLaunch is managed and operated by Basel Area Business & Innovation, the innovation and investment promotion agency for the Basel Area.We invite you to visit our site where you can read our success stories, learn more about the great ecosystem, and apply to participate.